Lifestance Health Group, Inc. (LFST) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Lifestance Health Group, Inc. (LFST)
A forensic read on Lifestance Health Group, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
6.5
Distress distance
Clean
Earnings quality
3
Forensic signals
94.9
P / E (ttm)
0.6%
ROE
$4.6B
Market cap
13.9%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Lifestance Health Group, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 6.5, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
1.1%
FY2025
Return on invested capital.Return on invested capital is 1.1% in the latest fiscal year and rising across FY2023–FY2025 from -8.2%. After-tax operating profit was ($149M) in FY2023 and $19M in FY2025, with operating income at -17.9% of revenue in FY2023, -2.5% in FY2024 and 1.7% in FY2025. The capital base behind it barely moved across FY2023–FY2025 ($1.8B to $1.7B, -6%), so there has been little new capital for that return to be earned on.
+3.2%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +6% over the last 2 years to FY2025 (+3.2%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~3.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~6%.
5% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 5% of revenue and 68% of free cash flow in FY2025 — about $0.19 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 3.2% a year and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$1.42B
Revenue Growth YoY+13.9%
Revenue CAGR (2yr)+16.1%
Net Margin0.7%
Free Cash Flow$110.0M
Return on Equity0.6%
Debt / Equity0.18x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Lifestance Health Group, Inc.'s actual 10-K/10-Q/8-K filings?